H.C. Wainwright analyst Yi Chen lowered the firm’s price target on Barinthus Biotherapeutics to $5 from $8 and keeps a Buy rating on the shares. The company announced plans to prioritize its pipeline to focus on the development of VTP-300 for the treatment of chronic hepatitis B infection and VTP-1000 for celiac disease, the analyst tells investors in a research note. The firm says the restructuring should allow Barinthus to advance clinical programs of VTP-300 and VTP-1000 efficiently with existing resources,
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BRNS:
- Barinthus Bio Announces Strategic Pipeline Prioritization Following Positive Interim Data from VTP-300 in Chronic Hepatitis B Virus Infections
- Barinthus Biotherapeutics Breakthrough in Hepatitis B Treatment
- Barinthus presents EOT data from Phase 2a trial of imdusiran, VTP-300
- Barinthus Bio’s VTP-300 Trials Demonstrate Ability to Achieve Undetectable HBsAg levels and Statistical Significance in Lowering HBsAg Levels in People with Chronic Hepatitis B
- Arbutus announces preliminary EOT data from Phase 2a trial of imdusiran, VTP-300
Questions or Comments about the article? Write to editor@tipranks.com